LTRN Lantern Pharma Inc

Price (delayed)

$3.85

Market cap

$43.52M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.45

Enterprise value

$38.66M

?
Relative Growth: Rel. Growth: 13
Relative Strength: Rel. Strength: 55
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 7

Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. It leverages advances in machine learning, genomics, and artificial intelligence by ...

Highlights
The company's debt has shrunk by 70% YoY and by 25% QoQ
Lantern Pharma's EPS has increased by 21% YoY and by 8% from the previous quarter
The equity has plunged by 79% YoY and by 47% from the previous quarter
The quick ratio has plunged by 64% YoY and by 26% from the previous quarter

Key stats

What are the main financial stats of LTRN

LTRN stock price

How has the Lantern Pharma stock price performed over time
Intraday
13.24%
1 week
10%
1 month
72.65%
1 year
15.27%
YTD
27.06%
QTD
181.02%

Financial performance

How have Lantern Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.61M
Net income
-$15.91M
Gross margin
N/A
Net margin
N/A
The operating income has increased by 22% year-on-year and by 8% since the previous quarter
The company's net income rose by 20% YoY and by 7% QoQ

Price vs fundamentals

How does LTRN's price correlate with its fundamentals

Growth

What is Lantern Pharma's growth rate over time

Valuation

What is Lantern Pharma stock price valuation
P/E
N/A
P/B
12.58
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Lantern Pharma's EPS has increased by 21% YoY and by 8% from the previous quarter
LTRN's price to book (P/B) is 158% higher than its last 4 quarters average of 4.3
The equity has plunged by 79% YoY and by 47% from the previous quarter

Efficiency

How efficient is Lantern Pharma business performance
The ROE has plunged by 138% YoY and by 31% from the previous quarter
The return on invested capital has dropped by 122% since the previous quarter
Lantern Pharma's return on assets has shrunk by 83% YoY and by 19% QoQ

Dividends

What is LTRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LTRN.

Financial health

How did Lantern Pharma financials performed over time
The total assets is 91% greater than the total liabilities
The total assets has dropped by 66% year-on-year and by 35% since the previous quarter
The quick ratio has plunged by 64% YoY and by 26% from the previous quarter
The company's debt is 98% lower than its equity
The debt to equity has soared by 100% from the previous quarter and by 100% YoY
The equity has plunged by 79% YoY and by 47% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.